Experts say continuous manufacturing adoption uneven; Ipsen releasing batch of drug that has been in short supply;

> French drugmaker Ipsen says that in collaboration with the FDA, it is releasing in November an additional batch of Increlex, its rare disease drug, supplies of which were interrupted when its contractor Lonza decided to shut down a plan in the U.S. that the FDA had cited for manufacturing lapses. Release

> In part 2 of its annual report, experts with CPhI say that drugmakers are moving toward continuous processing but that the adoption will be uneven. Release

> CDMO Patheon is reworking its brand with a new logo and a new tagline, "A healthier world delivered." Release

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.